Related Experiment Video

Updated: Aug 6, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Cancer targets in the Ras pathway

P Rodriguez-Viciana1, O Tetsu, K Oda

  • 1Cancer Research Institute, University of California San Francisco Comprehensive Cancer Center, 94115, USA.

Cold Spring Harbor Symposia on Quantitative Biology
|July 28, 2006
PubMed

Insights

Ras proteins are key drivers in human cancers, with mutations in H-Ras, N-Ras, and K-Ras varying by tumor type. Understanding these mutations and their downstream effects is crucial for developing targeted cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ras proteins (including H-Ras, N-Ras, and K-Ras) are directly implicated in the pathogenesis of human cancers.
  • The varying frequencies of Ras mutations across different tumor types remain poorly understood.
  • Other Ras superfamily members and downstream pathways (e.g., B-Raf, PTEN, PI 3' kinase) also contribute to oncogenesis.

Purpose of the Study:

  • To explore the role of Ras proteins and their associated pathways in human cancer.
  • To investigate the complex interactions and mutational patterns within the Ras signaling network.
  • To assess the therapeutic potential and validation status of targets within the Ras pathway.

Main Methods:

  • Analysis of mutation frequencies of H-Ras, N-Ras, and K-Ras in various cancer types.
  • Examination of mutations in downstream effectors such as B-Raf, PTEN, and PI 3' kinase.
  • Review of drug development status for inhibitors targeting the Ras pathway, including Sorafenib.

Main Results:

  • Mutations in Ras proteins are a direct cause of human cancers.
  • Mutational patterns in Ras and its effectors can be mutually exclusive or coexistent, indicating complex pathway regulation.
  • Drugs targeting the Ras pathway, like Sorafenib, are in clinical development, with some approved for specific indications.

Conclusions:

  • Ras pathway mutations are critical in cancer development and progression.
  • The intricate interplay between Ras and its effectors presents challenges and opportunities for targeted therapy.
  • Despite progress, the therapeutic validation of Ras pathway targets requires further investigation.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...